GSK2126458 is a potent inhibitor of common activating mutants of p110α, p110β, p110γ, p110δ, mTORC1 and mTORC2 with Ki of 0.019 nM, 0.13 nM, 0.024 nM, 0.06 nM, 0.18 nM and 0.3 nM, respectively. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival. GSK2126458 inhibited AKT signaling and it showed effects on p70S6K and rpS6 signaling with effects resembling those of rapamycin. PI3K inhibitor GSK2126458 causes a significant reduction in the levels of pAkt-S473 in T47D and BT474 cells with an IC50 of 0.41 nM and 0.18 nM, respectively. GSK2126458 leads to a G1 cell cycle arrest and produces the inhibitory effect on cell proliferation in a large panel of cell lines, including T47D and BT474 breast cancer lines with IC50 of 3 nM and 2.4 nM, respectively. GSK2126458 had a width of inhibitory activity for potent cell growth and induced cell death in various human tumor cells.
| Cell Experiment | |
|---|---|
| Cell lines | BT474, HCC1954 and T-47D cells |
| Preparation method | BT474, HCC1954 and T-47D (human breast) were cultured in RPMI-1640 containing 10% fetal bovine serum at 37 in 5% CO2 incubator.Cells were then plated in 384 well black flat bottom polystyrene (Greiner #781086) in 48 µl of culture media per well at 1,000 cells/well. Following 72 hours of incubation with compounds each plate was developed and read. CellTiter-Glo reagent was added to assay plates using a volume equivalent to the cell culture volume in the wells. |
| Concentrations | 0~1μ M |
| Incubation time | 72h |
| Animal Experiment | |
|---|---|
| Animal models | BT474 human tumor xenografts in mice |
| Formulation | DMSO/H2O |
| Dosages | 0.3, 1 and 3mg/kg once daily for 5 days/week for 3 weeks |
| Administration | oral |
| Molecular Weight | 505.5 |
| Formula | C25H17F2N5O3S |
| CAS Number | 1086062-66-9 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related PI3K Products |
|---|
| STX-478
STX-478 is a mutation-selective variant PI3Ka inhibitor for studies related to breast cancer and other solid tumors. |
| Hirsutenone
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. |
| Boc-L-cyclobutylglycine
Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis. |
| PI-273
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis. |
| Chaetominine
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
